A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132

Launched by BRISTOL-MYERS SQUIBB · Mar 12, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a medication called Deucravacitinib for people with certain types of lupus, specifically Systemic Lupus Erythematosus (SLE) and Discoid or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE). This study aims to continue treatment for individuals who have previously participated in related studies (IM011074 or IM011132) and have completed the required treatment period. The goal is to see if continuing Deucravacitinib can provide further benefits.

To be eligible for this trial, participants must have finished either of the previous studies and be judged by their doctor to potentially benefit from ongoing treatment. They should have received the study medication within the last 60 days. However, individuals with active Tuberculosis or certain other medical conditions may not be eligible. While the study is not yet recruiting participants, those who do join can expect to continue receiving Deucravacitinib and will be monitored closely for their health and safety throughout the trial.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • Participants must have completed Study IM011074 or Study IM011132 through the protocol-required treatment period.
• • Participants must be, based on the physician's medical judgement, likely to receive benefit from receiving treatment with deucravacitinib.
• • Participants must have received IP within 60 days of enrollment. Exceptions may be granted based upon consultation with BMS.
• • Exclusion Criteria
• • Participants must not have any disease or medical condition that, in the opinion of the physician, would make the subject unsuitable for this protocol, would interfere with the interpretation of subject safety or considered unsuitable by the physician for any other reason.
• • Participants must not have any evidence of active Tuberculosis (TB).
• • Other protocol-defined Inclusion/Exclusion criteria apply.